The biotech company was once widely regarded as one of the most dependable growth stocks on the ASX. But over the past few ...

Australian biotech giant CSL extended losses on Thursday, lingering near decade lows, after the U.S. military scrapped its ...

Carlisle Companies' Q1 sales performance reflects macroeconomic weakness but also a transitory headwind from harsh winter ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell short of the market’s revenue expectations in Q1 ...

Carlisle Companies is positioned for strong growth, driven by aging U.S. commercial roofs and stricter energy standards. Find ...

CSL’s growth slowed, and its premium valuation reset hard. The post What on earth's going on with CSL shares? appeared first ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Carlisle (CSL).

CSL Limited has reported the latest daily progress of its on-market share buy-back program for its ordinary fully paid shares. The company disclosed that it has repurchased a cumulative 5,550,945 ...

ASX companies are increasing manufacturing operations in the US offering resilience to tariffs and closer proximity to ...

CSL Ltd (ASX: CSL) shares are being hammered once again on Tuesday. In morning trade, the biotech giant's shares are down a disappointing 17% to a new 52-week low of $176.23. Investors have been ...